Intellia Therapeutics (NTLA) Receivables - Other (2015 - 2023)

Intellia Therapeutics (NTLA) has 9 years of Receivables - Other data on file, last reported at $1.0 million in Q4 2023.

• Quarterly Receivables - Other fell 37.5% year-over-year to $1.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.0 million (down 37.5% YoY) and the FY2023 annual result came in at $1.0 million, down 37.5% from the prior year.
• Receivables - Other was little changed at $1.0 million in Q4 2023 per NTLA's latest filing, from $1.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $8.4 million in Q1 2020 and bottomed at $100000.0 in Q4 2021.
• The 5-year median for Receivables - Other is $1.0 million (2019), against an average of $1.8 million.
• The widest annual swing landed in 2021, when Receivables - Other sank 88.1%; it then jumped 1500.0% in 2022.
• Tracing NTLA's Receivables - Other over 5 years: stood at $3.6 million in 2019, then tumbled by 66.67% to $1.2 million in 2020, then slumped by 91.67% to $100000.0 in 2021, then jumped by 1500.0% to $1.6 million in 2022, then sank by 37.5% to $1.0 million in 2023.
• Per Business Quant, the three latest NTLA Receivables - Other figures stand at $1.0 million (Q4 2023), $1.0 million (Q3 2023), and $1.4 million (Q2 2023).

Peer Comparison